Bryan King, MD
Cardiovascular Disease · Troy, OHNPI 1023301876
Payments from drug & device makers
Across 8 payments — averaging $79.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Maquet Cardiovascular L.L.C.$539
- Abbott$27
- Amgen$25
- Abiomed$20
- Boston Scientific$16
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$8
What the payments were for
- Travel & lodging$53985%
- Food & beverage$9715%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Maquet Cardiovascular L.L.C. | 2 | $539 |
| Abbott | 2 | $27 |
| Amgen | 1 | $25 |
| Abiomed | 1 | $20 |
| Boston Scientific | 1 | $16 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$635 in reported general payments places this provider in the 30th percentile of 827 cardiovascular disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 349 | $360,796 |
| XareltoRivaroxaban | 129 | $113,175 |
| Repatha SureclickEvolocumab | 17 | $25,758 |
| EntrestoSacubitril/Valsartan | 19 | $24,007 |
| BrilintaTicagrelor | 28 | $19,343 |
| Prasugrel Hcl | 11 | $5,141 |
| Ranolazine ErRanolazine | 12 | $2,442 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 97 | $2,432 |
| Flecainide Acetate | 37 | $2,096 |
| Metoprolol Succinate | 160 | $1,840 |
| Metoprolol Tartrate | 321 | $1,576 |
| Atorvastatin Calcium | 270 | $1,570 |
| ClopidogrelClopidogrel Bisulfate | 193 | $1,446 |
| Midodrine Hcl | 20 | $1,333 |
| Digoxin | 36 | $975 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Troy
- Samir KapadiaCleveland$11.1M
- Steven NissenCleveland$5.3M
- Milind DesaiCleveland$5M
- Abraham LincoffCleveland$3.6M
- Carlos HubbardCleveland$3.1M
- Guilherme AttizzaniCleveland$2.8M
- Wai Hong TangCleveland$2.2M
- Bhola RamaMarion$2.1M
- Mazen HannaCleveland$1.6M
- Akber MohammedSpringfield$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.